Biomerica 미래 성장

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Biomerica 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

NasdaqCM:BMRA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
8/31/2024	6	-6	-5	-5	N/A
5/31/2024	5	-6	-5	-5	N/A
2/29/2024	5	-6	-5	-5	N/A
11/30/2023	6	-6	-5	-5	N/A
8/31/2023	5	-6	-6	-6	N/A
5/31/2023	5	-7	-6	-5	N/A
2/28/2023	10	-7	-9	-9	N/A
11/30/2022	16	-6	-5	-5	N/A
8/31/2022	19	-5	-2	-2	N/A
5/31/2022	19	-5	-1	0	N/A
2/28/2022	15	-4	3	3	N/A
11/30/2021	11	-7	-1	-1	N/A
8/31/2021	7	-7	-4	-4	N/A
5/31/2021	7	-7	-6	-5	N/A
2/28/2021	9	-6	-8	-8	N/A
11/30/2020	6	-5	-7	-7	N/A
8/31/2020	7	-4	-6	-6	N/A
5/31/2020	7	-2	-4	-4	N/A
2/29/2020	5	-3	-2	-2	N/A
11/30/2019	5	-2	-2	-2	N/A
8/31/2019	5	-2	-2	-1	N/A
5/31/2019	5	-2	-2	-2	N/A
2/28/2019	5	-2	-2	-2	N/A
11/30/2018	5	-2	-2	-2	N/A
8/31/2018	5	-2	-2	-2	N/A
5/31/2018	6	-1	N/A	-1	N/A
2/28/2018	6	-1	N/A	-1	N/A
11/30/2017	6	-1	N/A	-1	N/A
8/31/2017	6	-1	N/A	-1	N/A
5/31/2017	6	-1	N/A	-1	N/A
2/28/2017	6	-2	N/A	0	N/A
11/30/2016	6	-2	N/A	0	N/A
8/31/2016	5	-1	N/A	0	N/A
5/31/2016	5	-1	N/A	0	N/A
2/29/2016	5	0	N/A	0	N/A
11/30/2015	5	0	N/A	-1	N/A
8/31/2015	5	0	N/A	-1	N/A
5/31/2015	5	0	N/A	0	N/A
2/28/2015	5	0	N/A	0	N/A
11/30/2014	5	0	N/A	0	N/A
8/31/2014	5	0	N/A	0	N/A
5/31/2014	5	0	N/A	-1	N/A
2/28/2014	5	0	N/A	-1	N/A
11/30/2013	5	0	N/A	0	N/A

애널리스트 미래 성장 예측

수입 대 저축률: BMRA 의 예상 수익 증가율이 절약률( 2.5% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: BMRA 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: BMRA 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: BMRA 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: BMRA 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: BMRA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Biomerica 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Price target increased to US$13.00

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Analysts lower revenue estimates to US$8.51m

Recent updates

Biomerica, Inc. Announces Direct-To-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain

First quarter 2025 earnings released: US$0.078 loss per share (vs US$0.067 loss in 1Q 2024)

Biomerica, Inc., Annual General Meeting, Dec 13, 2024

New major risk - Financial position

Full year 2024 earnings released: US$0.35 loss per share (vs US$0.50 loss in FY 2023)

Biomerica, Inc. Launches At-Home Sample Collection for inFoods IBS, Significantly Expanding Access for Millions of IBS Sufferers

Biomerica, Inc. Announces Infoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024

Biomerica, Inc. has filed a Follow-on Equity Offering in the amount of $5.5 million.

Biomerica Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2023)

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.12 loss in 2Q 2023)

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.16 loss in 1Q 2023)

Biomerica, Inc., Annual General Meeting, Dec 07, 2023

Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

Jack Kenny Joins Biomerica’S Board of Directors

Full year 2023 earnings released: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.008 loss in 3Q 2022)

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.089 loss in 2Q 2022)

Biomerica Appoints Brian E. Lacy, to the Company’s Scientific Advisory Board

Steve Sloan to Step Down as Chief Financial Officer of Biomerica, Inc

Biomerica, Inc. Announces Board Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1Q 2022)

Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test

Biomerica, Inc., Annual General Meeting, Dec 07, 2022

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

Biomerica, Inc. Appoints Robert Carlson as Chief Commercial Officer

Full year 2022 earnings released: US$0.36 loss per share (vs US$0.62 loss in FY 2021)

Biomerica reports FY results

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2021)

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Biomerica, Inc. Expects Completion of Patient Enrollment for Its Infoods Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial This Week

Price target increased to US$13.00

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.23 loss in FY 2020)

Biomerica Announces Notice of Allowance for Patent on Product Used to Diagnose and Treat Depression

Biomerica, Inc. Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment

Biomerica (BMRA) Investor Presentation - Slideshow

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.088 loss in 3Q 2020)

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

New 90-day high: US$8.00

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

New 90-day high: US$7.50

Second quarter 2021 earnings released: US$0.13 loss per share

Earnings beat expectations, revenue disappoints

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Biomerica, Inc. Receives CE Mark for its New Covid-19 Rapid Antigen Test for Detection of Covid-19 Infection

Analysts lower revenue estimates to US$8.51m

Biomerica soars as its COVID-19 antigen test wins European nod

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

New 90-day low: US$5.38

Biomerica, Inc. Announces Corporate Secretary Changes

Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment

Biomerica clinical trial for IBS nears enrollment completion